CycloserineThird Party Manufacturing in India

Cycloserine is a broad-spectrum antibiotic that exerts its bactericidal effect by disrupting bacterial cell wall synthesis through a unique dual-enzyme inhibition mechanism. As a structural analogue of D-alanine, cycloserine competitively inhibits two key enzymes in the peptidoglycan biosynthesis pathway: alanine racemase, which catalyses the conversion of L-alanine to D-alanine, and D-alanine:D-alanine ligase, which joins two D-alanine molecules to form the D-alanyl-D-alanine dipeptide. This dipeptide is an essential building block of the pentapeptide side chain that cross-links the peptidoglycan polymer in bacterial cell walls. By blocking both enzymes, cycloserine effectively starves the cell of the D-alanine residues needed for peptidoglycan assembly, leading to a weakened cell wall, osmotic instability, and ultimately bacterial cell lysis. The drug is particularly effective against Mycobacterium tuberculosis because mycobacteria depend heavily on a robust peptidoglycan layer for their structural integrity. Unlike first-line anti-TB agents that target mycolic acid synthesis or RNA polymerase, cycloserine attacks a completely different pathway, making it valuable against drug-resistant strains. Clinicians monitor cycloserine therapy closely because the drug crosses the blood-brain barrier and can act as a partial agonist at the glycine site of NMDA receptors, which accounts for its neuropsychiatric side effect profile and necessitates careful dose adjustment in patients.

Therapeutic Uses

Cycloserine is a second-line anti-tuberculosis agent primarily used in multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) regimens.

• Multi-Drug Resistant Tuberculosis (MDR-TB): Cycloserine is a core component of WHO-recommended MDR-TB treatment regimens, used in combination with other second-line agents such as fluoroquinolones, aminoglycosides, and linezolid.
• Extensively Drug-Resistant Tuberculosis (XDR-TB): When first-line and some second-line drugs fail, cycloserine remains one of the few available oral agents with activity against XDR-TB strains.
• Nocardiosis: Occasionally used in combination with sulfonamides for the treatment of Nocardia infections.
• Urinary Tract Infections: Rarely used for UTIs caused by Gram-negative organisms susceptible to cycloserine, though this indication has largely been replaced by safer alternatives.

Why Manufacturers Choose Cycloserine

Cycloserine holds a critical position in the global TB control strategy as an essential second-line agent. With India bearing one of the highest burdens of MDR-TB cases worldwide, there is consistent and growing demand for cycloserine tablets from both the public health sector under the National TB Elimination Programme and private healthcare providers. The molecule has a well-established manufacturing process, and Indian pharmaceutical companies have developed significant expertise in its synthesis, achieving yields that make it commercially viable despite its relatively modest pricing. The API is sourced primarily from China and India, with Indian manufacturers well-positioned in the downstream formulation market. Given the WHO's continued emphasis on TB elimination and the rising prevalence of drug-resistant strains, cycloserine remains one of the most strategically important molecules for contract manufacturing and PCD franchise operations in the anti-TB segment.